Proteomics International Laboratories Ltd (ASX:PIQ) Managing Director Dr. Richard Lipscombe is Interviewed about the ProMarker Suite of Diagnostic Tests

Proteomics International Laboratories Ltd (ASX:PIQ) Managing Director Dr. Richard Lipscombe is Interviewed about the ProMarker Suite of Diagnostic Tests.

In this interview, Dr. Lipscombe explains the ProMarkerD, ProMarkerENDO, ProMarkerESO and OxiDx diagnostic tests that considerably reduce the cost to patient and health care systems by providing a simple blood test replacing otherwise invasive surgery.

Dr. Lipscombe also details the commercial model for the global access to these tests using a "traditional" and "hybrid" approach.

First sales of the predictive diagnostic tests are due first quarter 2025.

To Watch the Interview, please visit:
https://www.abnnewswire.net/lnk/07X1Q212

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations and Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

Matthew Wright
Media and Public Relations
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

News Provided by ABN Newswire